Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has been updated to include new drug and dietary supplement information related to the MK-3475-189 Japan Extension Study, while significant details about the study's design and participant criteria have been removed.SummaryDifference25%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.